ClinicalTrials.gg
RecruitingNCT07940153AIMASUpdated Nov 16, 2026

Development and Validation of an AI-Driven Motor Skill Assessment System for Children

An observational study in Motor Development in Children, Developmental Coordination Disorder and Cerebral Palsy, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Chang Gung Memorial Hospital · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
470
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This study aims to develop and validate the AI-Integrated Motor Assessment System (AIMAS) for evaluating motor skills in children aged 6 to 12 years. The study will include typically developing children and children with developmental delay or motor-related developmental disorders.

Participants will complete standardized gross and fine motor tasks while their movements are video-recorded for AI-based analysis. Some participants will also complete a standardized clinical motor assessment for comparison.

The study will evaluate the reliability, validity, and accuracy of AIMAS, including its ability to identify children with motor difficulties. The long-term goal is to establish AIMAS as an accessible and efficient screening tool that can support earlier referral for further professional assessment.

Read the detailed description

This three-year study will develop and validate the AI-Integrated Motor Assessment System (AIMAS), an AI-based platform that uses video-recorded motor tasks and pose-estimation analysis to assess children's motor performance.

In Year 1, the study will expand the motion dataset, train the AI model, and evaluate reliability and validity. In Year 2, the model will be tested in a new population using measures including ROC curves, AUC, sensitivity, and specificity, and a motor developmental delay risk score will be developed. In Year 3, AIMAS will be evaluated in clinical and educational settings for feasibility, accuracy, and agreement with professional motor assessments.

Approximately 470 children aged 6 to 12 years will be enrolled, including typically developing children and children with developmental delay or motor-related developmental disorders. Participants will complete a one-time assessment involving gross and fine motor tasks, with video recordings collected for AI analysis. A subset will also complete a standardized motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency, for criterion-related validation.

The overall goal is to establish AIMAS as a reliable, valid, and scalable screening tool for early identification of motor difficulties in children.

02

Conditions studied

  • Motor Development in Children
  • Developmental Coordination Disorder
  • Cerebral Palsy
  • Developmental Delay

Keywords

  • Artificial Intelligence
  • Motor Skill Assessment
  • Motor Development
  • Developmental Coordination Disorder
  • Developmental Delay
  • Pose Estimation
  • Video-Based Assessment
  • AIMAS
  • Bruininks-Oseretsky Test of Motor Proficiency
03

In context

Motor Skills Disorders

105 studies on the registry are indexed under Motor Skills Disorders; 29 are open to participants now.

This study's planned enrollment of 470 is above the median of 92 across 28 observational studies indexed under Motor Skills Disorders.

Browse Motor Skills Disorders studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will include children aged 6 to 12 years recruited from collaborating hospital outpatient clinics and elementary schools. Participants will include typically developing children and children with developmental delay or motor-related developmental disorders, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or other clinician-confirmed developmental motor disorders.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Developmental Delay With Motor Disorder Group:

  • Children aged 6 to 12 years.
  • Able to understand and follow the motor instructions required for the study.
  • Clinical diagnosis of developmental delay with motor disorder, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or another clinician-confirmed developmental motor disorder.

Typically Developing Group:

  • Children aged 6 to 12 years.
  • Able to understand and follow the motor instructions required for the study.
  • Typical developmental milestones with no history of developmental delay or diagnosed developmental disorder.

Exclusion criteria

Exclusion Criteria:

Developmental Delay With Motor Disorder Group:

  • Acute illness that makes participation unsuitable.
  • Degenerative or progressive neurological disease.
  • Unable to safely complete motor tasks because of conditions such as fracture, physical discomfort, or pain.

Typically Developing Group:

  • Prior diagnosis of developmental delay, motor impairment, or another condition affecting motor performance.
  • Neurological disorder, genetic syndrome, or major congenital or acquired condition that could influence motor ability.
  • Possession of a disability certificate or prior professional identification of significant developmental concerns.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
470 participants (estimated)
Patient registry
No

Groups and cohorts

  • Typically Developing Group

    Children aged 6 to 12 years with typical development will complete standardized gross and fine motor assessments with video recording for AI-based analysis using the AI-Integrated Motor Assessment System (AIMAS).

    Diagnostic Test: AI-Integrated Motor Assessment System (AIMAS)

  • Developmental Delay With Motor Disorder Group

    Children aged 6 to 12 years with developmental delay or motor-related developmental disorders will complete standardized gross and fine motor assessments with video recording for AI-based analysis using AIMAS.

    Diagnostic Test: AI-Integrated Motor Assessment System (AIMAS)

Interventions

  • Diagnostic testAI-Integrated Motor Assessment System (AIMAS)

    The AI-Integrated Motor Assessment System (AIMAS) is a video-based motor assessment system that uses artificial intelligence and pose-estimation analysis to evaluate gross and fine motor performance in children. Participants complete standardized motor tasks while their movements are video-recorded for AI-based analysis. A subset of participants also completes a standardized clinical motor assessment for validation of AIMAS results.

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy of AIMAS for Identifying Motor Developmental Difficulties

    Diagnostic accuracy of the AI-Integrated Motor Assessment System (AIMAS) in distinguishing typically developing children from children with developmental delay or motor-related developmental disorders. Classification performance will be quantified using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity.

    Time frame: Baseline (Day 1)

  2. Reliability of AIMAS

    Reliability of the AI-Integrated Motor Assessment System (AIMAS) will be quantified using intraclass correlation coefficients (ICC) for inter-rater and test-retest reliability. Inter-rater reliability will be determined by comparing AIMAS measurements obtained from independent raters, while test-retest reliability will be assessed using repeated motor assessments of the same participants. Consistency of AI-based joint and pose estimation will also be examined.

    Time frame: Baseline (Day 1) and repeat assessment (Week 1)

  3. Criterion Validity of AIMAS

    Criterion-related validity of the AI-Integrated Motor Assessment System (AIMAS) will be examined by comparing AIMAS-derived motor performance scores with scores obtained from a standardized clinical motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency (BOT), in a subset of participants. Associations between AIMAS scores and standardized assessment scores will be quantified using correlation coefficients.

    Time frame: Baseline (Day 1)

Secondary outcomes

  1. Group Differences in AIMAS-Derived Motor Task Performance

    Motor task performance will be compared between typically developing children and children with developmental delay or motor-related developmental disorders using quantitative measures derived from the AI-Integrated Motor Assessment System (AIMAS). Outcomes will include task completion time (seconds), task performance accuracy (percentage of correctly completed task components), and joint range of motion (degrees), as applicable to the standardized motor tasks. Between-group differences will be analyzed for each prespecified motor performance measure.

    Time frame: Baseline (Day 1)

  2. AIMAS-Derived Motor Developmental Delay Risk Score

    A motor developmental delay risk score will be generated using AIMAS-derived movement features and classification model outputs. The score will represent the estimated probability of motor developmental difficulties, ranging from 0 to 1, with higher values indicating greater predicted risk.

    Time frame: Baseline (Day 1)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940153
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Chia-Ling Chen
Contact
clingchen@gmail.com
+883-3-3281200 ext. 8148
Chia-Ling Chen
study director · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion